These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20653107)

  • 21. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Kaaijk P; van Straaten I; van de Waterbeemd B; Boot EP; Levels LM; van Dijken HH; van den Dobbelsteen GP
    Vaccine; 2013 Feb; 31(7):1065-71. PubMed ID: 23273968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.
    Koeberling O; Giuntini S; Seubert A; Granoff DM
    Clin Vaccine Immunol; 2009 Feb; 16(2):156-62. PubMed ID: 19109451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
    Williams JN; Weynants V; Poolman JT; Heckels JE; Christodoulides M
    Vaccine; 2014 Mar; 32(11):1280-6. PubMed ID: 24486354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.
    Pillai S; Howell A; Alexander K; Bentley BE; Jiang HQ; Ambrose K; Zhu D; Zlotnick G
    Vaccine; 2005 Mar; 23(17-18):2206-9. PubMed ID: 15755596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.
    Beernink PT; Shaughnessy J; Pajon R; Braga EM; Ram S; Granoff DM
    PLoS Pathog; 2012; 8(5):e1002688. PubMed ID: 22589720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
    Hou VC; Koeberling O; Welsch JA; Granoff DM
    J Infect Dis; 2005 Aug; 192(4):580-90. PubMed ID: 16028126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
    Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
    Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870.
    Koeberling O; Welsch JA; Granoff DM
    Vaccine; 2007 Feb; 25(10):1912-20. PubMed ID: 16677743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential.
    O'dwyer CA; Reddin K; Martin D; Taylor SC; Gorringe AR; Hudson MJ; Brodeur BR; Langford PR; Kroll JS
    Infect Immun; 2004 Nov; 72(11):6511-8. PubMed ID: 15501782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
    Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
    Zhu D; Zhang Y; Barniak V; Bernfield L; Howell A; Zlotnick G
    Infect Immun; 2005 Oct; 73(10):6838-45. PubMed ID: 16177362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
    Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
    Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.
    Wedege E; Lie K; Bolstad K; Weynants VE; Halstensen A; Herstad TK; Kreutzberger J; Nome L; Naess LM; Aase A
    Scand J Immunol; 2013 Jun; 77(6):452-9. PubMed ID: 23521186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.
    Moran EE; Burden R; Labrie JE; Wen Z; Wang XM; Zollinger WD; Zhang L; Pinto VB
    Clin Vaccine Immunol; 2012 May; 19(5):659-65. PubMed ID: 22461527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.